Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor.

npj drug discovery·2026
Same author

Post-discharge "continuum of care" clinical pathway (CP) for persons with severe neuro-disabilities - qualitative research to model needs-based community healthcare, capture the real-life care situation, and assess the appropriateness of the CP's concept with input from community- and hospital-based healthcare professionals.

Frontiers in neurology·2026
Same author

Reduction techniques for survival analysis.

Lifetime data analysis·2026
Same author

The Course of Rehabilitation of Ventilated and Tracheally Cannulated Patients in Neurological-Neurosurgical Early Rehabilitation.

Deutsches Arzteblatt international·2026
Same author

Interpretations of Menstrual Blood Appearance and Diagnostic Potential Among Social Media Users: Cross-Sectional Mixed Methods Social Media Listening Study.

Journal of medical Internet research·2026
Same author

Rethinking the role of synergy calculations in the next century of drug combination discovery.

Med (New York, N.Y.)·2026
Same journal

HuR degrader knocks down BRAF in cancer.

Nature reviews. Drug discovery·2026
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
09:21

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Published on: July 7, 2023

Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds.

Yan Feng1, Timothy J Mitchison, Andreas Bender

  • 1Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA. yan.feng@novartis.com

Nature Reviews. Drug Discovery
|July 2, 2009
PubMed
Summary
This summary is machine-generated.

Multi-parameter phenotypic profiling offers crucial insights into drug mechanisms and biological pathways. Early integration of these technologies enhances lead selection and optimization in drug discovery.

More Related Videos

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling
10:49

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling

Published on: September 20, 2016

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Related Experiment Videos

Last Updated: Jun 22, 2026

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons
09:21

Phenotypic Profiling of Human Stem Cell-Derived Midbrain Dopaminergic Neurons

Published on: July 7, 2023

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling
10:49

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling

Published on: September 20, 2016

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Discovery

Background:

  • Multi-parameter phenotypic profiling of small molecules is vital for understanding drug mechanisms of action.
  • It provides a systems-level view of biological pathways and their responses to therapeutic interventions.
  • Current drug discovery pipelines can benefit from increased attention to early-stage phenotypic profiling.

Purpose of the Study:

  • To summarize current technologies for multi-parameter phenotypic profiling in drug discovery.
  • To advocate for the earlier integration of phenotypic profiling into the drug discovery pipeline.
  • To highlight the potential of phenotypic profiling to improve lead selection and optimization.

Main Methods:

  • Review of existing mRNA-based multi-parameter profiling technologies.
  • Summary of protein-based multi-parameter profiling techniques.
  • Overview of imaging-based multi-parameter profiling methods in drug discovery.

Main Results:

  • Phenotypic profiling encompasses mRNA, protein, and imaging-based approaches.
  • These methods offer multi-parameter insights into small molecule effects.
  • Integration with target identification strategies is key.

Conclusions:

  • Earlier adoption of phenotypic profiling technologies can significantly improve drug discovery success rates.
  • Combining phenotypic profiling with experimental and in silico target identification enhances lead selection.
  • This integrated approach optimizes the drug discovery and development process.